FDA Approves New Treatment for Patients with Migraine

The U.S. Food and Drug Administration approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine.  

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine